| 1 |
32595277 | Cost-Utility Analysis of Saxagliptin/Dapagliflozin Versus Gliclazide and Insulin Glargine: Economic Implications of the Outcomes of the CVD-Real Studies I and II. | 2020 |
1 |
| 2 |
30758417 | The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data. | 2019 Jan |
1 |
| 3 |
29144061 | Saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: Results from the SUPER study, a randomized, double-blind, placebo-controlled trial. | 2018 Apr |
3 |
| 4 |
29482528 | Comparison of glycemic control and β-cell function in new onset T2DM patients with PCOS of metformin and saxagliptin monotherapy or combination treatment. | 2018 Feb 27 |
1 |
| 5 |
29727906 | Sequential Treatment Escalation with Dapagliflozin and Saxagliptin Improves Beta Cell Function in Type 2 Diabetic Patients on Previous Metformin Treatment: An Exploratory Mechanistic Study. | 2018 May |
2 |
| 6 |
29912623 | Saxagliptin Upregulates Nesfatin-1 Secretion and Ameliorates Insulin Resistance and Metabolic Profiles in Type 2 Diabetes Mellitus. | 2018 Sep |
3 |
| 7 |
27849380 | COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION. | 2017 Mar |
5 |
| 8 |
28405346 | Safety and efficacy of saxagliptin for glycemic control in non-critically ill hospitalized patients. | 2017 |
1 |
| 9 |
27787387 | Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes: A randomized, control, open-labeled trial. | 2016 Oct |
2 |
| 10 |
24889731 | Different effects of two dipeptidyl peptidase-4 inhibitors and glimepiride on β-cell function in a newly designed two-step hyperglycemic clamp. | 2015 Mar |
2 |
| 11 |
25656169 | Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study. | 2015 May |
1 |
| 12 |
26403305 | Saxagliptin: A Review in Type 2 Diabetes. | 2015 Oct |
1 |
| 13 |
26578430 | Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety. | 2015 Nov |
1 |
| 14 |
24627627 | Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination. | 2014 |
1 |
| 15 |
24947443 | Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes. | 2014 Aug |
1 |
| 16 |
23949898 | Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy. | 2013 Oct |
5 |
| 17 |
24741735 | | 2013 Nov |
1 |
| 18 |
28609031 | | 2013 Feb 13 |
1 |
| 19 |
22221000 | Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU. | 2012 Jan 22 |
3 |
| 20 |
22313154 | Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. | 2012 Apr |
2 |
| 21 |
19478198 | The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. | 2009 Sep |
1 |
| 22 |
19051153 | Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. | 2008 Dec |
1 |